Código QR

New Anticancer Drugs: Reliably Assessing “Value” While Addressing High Prices

Countries face challenges in paying for new drugs. High prices are driven in part by exploding drug development costs, which, in turn, are driven by essential but excessive regulation. Burdensome regulation also delays drug development, and this can translate into thousands of life-years lost. We ne...

Descripción completa

Guardado en:
Autores principales: David J. Stewart, John-Peter Bradford, Sandeep Sehdev, Tim Ramsay, Vishal Navani, Nigel S. B. Rawson, Di Maria Jiang, Joanna Gotfrit, Paul Wheatley-Price, Geoffrey Liu, Alan Kaplan, Silvana Spadafora, Shaun G. Goodman, Rebecca A. C. Auer, Gerald Batist
Formato: Artigo
Lenguaje:Inglês
Publicado: MDPI AG 2024-04-01
Colección:Current Oncology
Materias:
drug costs
drug value
ICER
QALY
Acceso en línea:https://www.mdpi.com/1718-7729/31/5/184
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares